PT-141 10mg reconstitution and dosage explained: how much bacteriostatic water to add, syringe units per dose, and the FDA-approved 1.75 mg protocol for women.
PT-141 (bremelanotide) is reconstituted by adding bacteriostatic water to the 10 mg vial, and the FDA-approved dose for premenopausal women with hypoactive sexual desire disorder is 1.75 mg injected subcutaneously about 45 minutes before anticipated activity. A 10 mg vial mixed with 1 mL of bacteriostatic water yields 10 mg/mL, which makes 1.75 mg equal 17.5 units on a U-100 insulin syringe. Mixing with 2 mL instead produces 5 mg/mL and a 35-unit dose, so the water volume you choose directly changes your syringe reading.
What a 10 mg PT-141 Vial Actually Represents
PT-141 is the research name for bremelanotide, a synthetic melanocortin receptor agonist. The FDA approved it in 2019 under the brand name Vyleesi for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD).
The drug works through melanocortin-4 receptors in the brain rather than through blood-flow pathways, which is why it is often discussed alongside PDE5 inhibitors rather than as a replacement for them. It is not a hormone, and it is not a casual aphrodisiac; it is a prescription peptide with measurable cardiovascular effects.
A 10 mg vial is a compounded or research-grade quantity. The brand-name auto-injector delivers a fixed 1.75 mg dose, so a 10 mg vial holds roughly 5.7 doses of the approved amount. That mismatch is exactly why reconstitution math matters so much.
PT-141 10 mg Reconstitution: Step by Step
Reconstitution means dissolving the lyophilized powder in a sterile liquid so it can be drawn into a syringe. Bacteriostatic water is the standard choice because its benzyl alcohol content slows bacterial growth and allows the vial to be used over several weeks.
- Wash your hands and wipe the vial stoppers and your work surface with alcohol swabs. Let everything air dry.
- Draw your chosen volume of bacteriostatic water into a syringe — most often 1 mL or 2 mL for a 10 mg vial.
- Insert the needle at a slight angle and aim the stream at the glass wall, not directly at the powder. Direct contact can degrade the peptide.
- Swirl the vial gently until the powder dissolves completely. Do not shake it; shaking creates foam and may damage the molecule.
- Label the vial with the date and the final concentration, then refrigerate it at 2–8 °C (36–46 °F). Protect it from light and never freeze it.
Most people finish the full pt-141 reconstitution and dosage process in about five minutes once supplies are laid out. Clean technique is not optional here, because a contaminated vial can cause injection-site infections.
Reconstitution Math: Milligrams to Syringe Units
The concentration in the vial determines how many units you draw. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL.
| Bacteriostatic water added | Concentration | 1 mg | 1.75 mg (approved dose) | 2 mg |
|---|---|---|---|---|
| 1 mL | 10 mg/mL | 10 units | 17.5 units | 20 units |
| 2 mL | 5 mg/mL | 20 units | 35 units | 40 units |
| 2.5 mL | 4 mg/mL | 25 units | 43.75 units | 50 units |
| 3 mL | 3.33 mg/mL | 30 units | 52.5 units | 60 units |
This chart is the most useful reference when you are converting the pt-141 10mg dosage in units, because the same milligram amount produces a different syringe reading at every concentration. Half-unit markings only help if your syringe includes them, so a 1.75 mg draw is genuinely easier to measure accurately when you use 2 mL of water.
PT-141 10 mg Dosage for Men vs. Women
The FDA label covers exactly one population: premenopausal women. Everything else is off-label or research-only, and that distinction drives most of the confusion surrounding this peptide.
| Group | Typical dose | Regulatory status | Frequency limit |
|---|---|---|---|
| Premenopausal women with HSDD | 1.75 mg subcutaneously | FDA-approved (Vyleesi) | Once per 24 hours; no more than 8 doses per month |
| Postmenopausal women | 1.75 mg subcutaneously in some studies | Not FDA-approved for this group | Once per 24 hours |
| Men | 1–2 mg subcutaneously in small studies and anecdotal reports | Not FDA-approved; investigational | Once per 24 hours |
Notably, the pt-141 10mg dosage women received in the pivotal trials was a flat 1.75 mg regardless of body weight. Published protocols describing a pt-141 10mg dosage for men have generally used 1 to 2 mg, and erectile-function studies in men have produced mixed results.
Timing, Side Effects, and Who Should Avoid It
Bremelanotide is injected subcutaneously into the abdomen or thigh, usually 45 minutes before anticipated activity, and the effect lasts roughly two to three hours. Nausea is the most commonly reported side effect, followed by flushing, headache, and injection-site reactions. Taking it with food may ease nausea but can also delay the onset of effects.
Other concerns include a temporary rise in blood pressure and focal hyperpigmentation of the skin, gums, or breast tissue with repeated use. The label carries a contraindication for people with uncontrolled hypertension or known cardiovascular disease.
Bremelanotide is not FDA-approved for use in men and is not a treatment for erectile dysfunction.
Anyone considering it should speak with a healthcare professional about blood pressure monitoring and possible interactions, particularly with antihypertensives, naltrexone, or SSRIs.
Common Reconstitution Mistakes to Avoid
- Using sterile water instead of bacteriostatic water, which shortens the multi-dose shelf life.
- Shaking the vial, which foams the peptide and may reduce potency.
- Forgetting to recalculate units after changing the water volume — a dose that was 17.5 units at 10 mg/mL becomes 35 units at 5 mg/mL.
- Storing the reconstituted vial at room temperature or in the freezer.
- Exceeding one dose in 24 hours; the label caps use at eight doses per month for a reason.
Writing the date, water volume, and concentration directly on the vial removes most dosing errors. If the powder will not dissolve after gentle swirling, contact the supplier instead of adding more water.
The Bottom Line on PT-141 10 mg
A 10 mg vial is convenient but demands accurate math, because the dose you draw depends entirely on how much water you add. The FDA-approved amount is 1.75 mg once per 24 hours for premenopausal women, and that equals 17.5 units at 1 mL of water or 35 units at 2 mL.
Bremelanotide is a prescription medication with real side effects, and compounded or research-grade vials are not the same as the approved product. Because the pt 141 10mg dosage depends completely on your mixing ratio, label the vial clearly before your first injection and review your plan with a clinician.
Frequently Asked Questions
How much bacteriostatic water should I add to a 10 mg vial of PT-141?
Most people add either 1 mL or 2 mL of bacteriostatic water. One milliliter creates a 10 mg/mL concentration, while 2 mL creates 5 mg/mL. The 2 mL option produces a larger, easier-to-read syringe volume, which is why it is often preferred for a 1.75 mg dose.
How many units is 1.75 mg of PT-141 on an insulin syringe?
The answer depends entirely on the concentration of your vial. With 1 mL of bacteriostatic water (10 mg/mL), 1.75 mg equals 17.5 units on a U-100 syringe. With 2 mL (5 mg/mL), the same dose equals 35 units.
Is PT-141 FDA-approved for men?
No. Bremelanotide is FDA-approved only as Vyleesi for premenopausal women with hypoactive sexual desire disorder. Male use remains off-label and investigational, and the FDA has not reviewed it for erectile dysfunction. Anyone using it should do so under medical supervision.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.